At a glance
ClinicalIndex Comparison RecordPhase 3Active· 1,126 enrolled
Drug / intervention
MEDI4736 (Durvalumab) +4 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase III, Randomized, Open-Label, Controlled, Multi-Center, Global Study of First-Line MEDI4736 (Durvalumab) Monotherapy and MEDI4736 (Durvalumab) in Combination With Tremelimumab Versus Standard of Care Chemotherapy in Patients With Unresectable Stage IV Urothelial Cancer
In Brief
A Phase 3 clinical trial evaluating MEDI4736 (Durvalumab), Tremelimumab, and 3 other interventions for Urothelial Cancer. Active but no longer recruiting, targeting 1,126 participants across 222 sites in 24 countries.
Detailed Summary
A Phase III, Randomized, Open-Label, Controlled, Multi-Center, Global Study of First-Line MEDI4736 (Durvalumab) Monotherapy and MEDI4736 (Durvalumab) in Combination with Tremelimumab Versus Standard of Care Chemotherapy in Patients with Stage IV Urothelial Cancer
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsUrothelial Cancer
CountriesAustralia, Austria, Belgium, Brazil, Canada, China, Denmark, France, Germany, Greece, Israel, Italy, Japan, Mexico, Netherlands, Poland, Portugal, Russia, South Korea, Spain, Taiwan, Turkey (Türkiye), United Kingdom, United States
Collaborators--
Timeline
Phase 3Active
201620172018201920202021202220232024202520262027
First PostedAug 2015
Enrollment StartNov 2015
Primary CompletionJan 2020
TodayJul 2026
Study CompletionDec 2026
First PostedAug 5, 2015
Enrollment StartNov 2, 2015
Primary CompletionJan 27, 2020
Study CompletionDec 31, 2026
TodayJul 2, 2026
Enrollment to primary: 4.2 yearsPosted 10.9 years ago
Interventions
MEDI4736 (Durvalumab)drug
IV infusion
Tremelimumabdrug
IV infusion
Cisplatindrug
IV infusion
Carboplatindrug
IV infusion
Gemcitabinedrug
IV infusion